The efficacy of poly-ICLC against Ebola-Zaire virus (EBOV) infection in mice and cynomolgus monkeys
- US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD (United States)
- US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD (United States); Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States)
- Oncovir, Inc., Washington, DC (United States)
The potential protection of poly-ICLC (Hiltonol®) a double stranded RNA (dsRNA) against EBOV infection was assessed with prophylactic and therapeutic administration to wild type and TLR3-negative mice, and in non-human primates (NHPs) by measuring EBOL serum titers, survival extension, and serum liver and kidney function markers. Various doses of aqueous and liposomal poly-ICLC monotherapy provided robust protection in otherwise lethal murine EBOV challenge models, when treatment is started on the day 0 or one day after virus challenge. There was no advantage of liposomal vs. the aqueous poly-ICLC form. Protection appeared to be independent of TLR-3. NHPs treated with poly-ICLC and challenged with EBOV survived longer but eventually succumbed to Ebola infection. Nevertheless, the liver and kidney serum markers were markedly reduced in the infected and treated NHPs. Finally, in the two longest surviving poly-ICLC- treated NHPs, the day 10 serum EBOV titer was reduced 2.1 and 30 fold respectively.
- Research Organization:
- Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States)
- Sponsoring Organization:
- USDOE National Nuclear Security Administration (NNSA); National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH)
- Grant/Contract Number:
- AC52-07NA27344; 1R01AI067505-01
- OSTI ID:
- 1890794
- Report Number(s):
- LLNL-JRNL-731581; 882760
- Journal Information:
- Antiviral Research, Vol. 163; ISSN 0166-3542
- Publisher:
- ElsevierCopyright Statement
- Country of Publication:
- United States
- Language:
- English
Similar Records
Characterization of the therapeutic effect of antibodies targeting the Ebola glycoprotein using a novel BSL2-compliant rVSVΔG-EBOV-GP infection model
Ebola VP40 in Exosomes Can Cause Immune Cell Dysfunction